Cancers & treatments·Regimen libraryCurative

Stanford V

Checked 2026-09-09

Historical 12-week regimen with consolidative radiotherapy for advanced Hodgkin lymphoma; not superior to ABVD in the US Intergroup E2496 trial

Also called STANFORD V.

One cycle

every 28 days × 3 · about 12 weeks in total

28-day cycle × 3 (12 weeks), then radiotherapy to sites over 5 cm (about 12 weeks)IntravenousOral Daily oral course

Components

Drug	Dose	Route	Days
Doxorubicin Cytotoxic chemotherapy (anthracycline)	25 mg/m²	IV	D1, 15
Vinblastine Vinca alkaloid (microtubule inhibitor)	6 mg/m²	IV	D1, 15
Mechlorethamine Alkylating agent (nitrogen mustard); intravenous and topical gel	6 mg/m²	IV	D1
Vincristine Vinca alkaloid (microtubule inhibitor)	1.4 mg/m² (maximum 2 mg)	IV	D8, 22
Bleomycin Glycopeptide antibiotic (DNA-cleaving)	5 units/m²	IV	D8, 22
Etoposide Topoisomerase II inhibitor (podophyllotoxin derivative)	60 mg/m²	IV	D15, 16
Prednisone Glucocorticoid	40 mg/m² every other day	Oral	D1-28

Cycles

3 (12 weeks), then radiotherapy to sites over 5 cm

28-day cycle

Emetogenicity

Moderate (30-90%)

G-CSF

Not routine

Notes

Designed at Stanford to cut cumulative doxorubicin and bleomycin by shortening chemotherapy and relying on radiotherapy; E2496 showed no advantage over ABVD, so it is rarely used now.
Mechlorethamine has been in and out of supply; cyclophosphamide was substituted in some centres.

Used in

Hodgkin lymphoma

Products

DoxorubicinVinblastineMechlorethamine (chlormethine)VincristineBleomycinEtoposidePrednisone

Source

Gordon (E2496), JCO 2013: ABVD versus Stanford V in locally extensive and advanced Hodgkin lymphoma

Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.